Humacyte (HUMA) to Release Earnings on Friday

Humacyte (NASDAQ:HUMA) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Friday, May 9th. Analysts expect Humacyte to post earnings of ($0.19) per share and revenue of $0.46 million for the quarter.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The firm had revenue of $7.23 million during the quarter, compared to the consensus estimate of $0.64 million. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Stock Down 2.4 %

Shares of NASDAQ:HUMA opened at $1.23 on Wednesday. The firm has a market capitalization of $190.80 million, a PE ratio of -0.92 and a beta of 1.64. The company has a 50-day moving average price of $2.07 and a two-hundred day moving average price of $3.70. Humacyte has a twelve month low of $1.15 and a twelve month high of $9.97.

Insider Buying and Selling at Humacyte

In related news, CFO Dale A. Sander acquired 20,000 shares of the company’s stock in a transaction dated Thursday, April 10th. The stock was bought at an average cost of $1.53 per share, with a total value of $30,600.00. Following the acquisition, the chief financial officer now owns 40,600 shares of the company’s stock, valued at approximately $62,118. The trade was a 97.09 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathleen Sebelius bought 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 8th. The stock was bought at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares of the company’s stock, valued at $120,393.24. This represents a 121.34 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 83,993 shares of company stock valued at $118,224 in the last 90 days. Corporate insiders own 11.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HUMA. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Wednesday, March 26th. Finally, Benchmark restated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Humacyte currently has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.